AEON BIOPHARMA INC (AEON) Forecast, Price Target & Analyst Ratings

NYSEARCA:AEON • US00791X2099

Current stock price

1.06 USD
-0.06 (-5.36%)
At close:
1.0875 USD
+0.03 (+2.59%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AEON BIOPHARMA INC (AEON).

Forecast Snapshot

Consensus Price Target

Price Target
$5.30
+ 400.38% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q4 / 2025
EPS Estimate
-$0.13
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$5.30
Upside
+ 400.38%
From current price of $1.06 to mean target of $5.30, Based on 8 analyst forecasts
Low
$5.05
Median
$5.30
High
$5.67

Price Target Revisions

1 Month
0.00%
3 Months
-14.75%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for AEON. The average price target is 5.3 USD. This implies a price increase of 400.38% is expected in the next year compared to the current price of 1.06.
The average price target has been revised downward by 14.75% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

AEON Current Analyst RatingAEON Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

AEON Historical Analyst RatingsAEON Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
AEON was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about AEON.
In the previous month the buy percentage consensus was at a similar level.
AEON was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-10-08Aegis CapitalReiterate Buy -> Buy
2024-10-01HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-14HC Wainwright & Co.Maintains Buy -> Buy
2024-07-10HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-30HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-15HC Wainwright & Co.Maintains Buy -> Buy
2024-05-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-04-17HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-18HC Wainwright & Co.Initiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q4 / 2025
EPS Estimate
-$0.13
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
99.04%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
AEON revenue by date.AEON revenue by date.
3.36MN/A
-100.00%		N/AN/A2.407M36.72M
1,425.55%		77.52M
111.11%		208.08M
168.42%
EBITDA
YoY % growth
AEON ebitda by date.AEON ebitda by date.
-53.09MN/A
100.00%		N/AN/A
-31.14%		N/A
100.03%		N/A
562,069.23%		N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
AEON ebit by date.AEON ebit by date.
-53.97MN/A
100.00%		N/AN/A
-31.31%		-61.718M
99.82%		-97.704M
84,966.28%		-14.996M
-120.55%		-35.797M
-138.71%		-35.117M
1.90%		27.491M
178.29%		193.26M
602.99%		372.88M
92.94%
Operating Margin
AEON operating margin by date.AEON operating margin by date.
-1,606.25%N/AN/AN/AN/AN/AN/AN/A-1,458.93%74.87%249.30%179.20%
EPS
YoY % growth
AEON eps by date.AEON eps by date.
N/AN/AN/AN/A-85.9252.88
161.54%		-0.62
-101.18%		-0.71
-14.75%		-0.43
40.00%		0.23
154.76%		1.67
613.04%		2.91
73.78%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 25
EPS
Q2Q % growth		-0.13
99.04%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/A
EBIT
Q2Q % growth		-3.978M
-71.39%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

AEON Yearly Revenue VS EstimatesAEON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2027 2028 2029 2030 50M 100M 150M 200M
AEON Yearly EPS VS EstimatesAEON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 40 -40 -60 -80

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-26.16%
EPS Next 5 Year
-49.88%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

AEON BIOPHARMA INC / AEON Forecast FAQ

What do analysts expect the price target to be for AEON BIOPHARMA INC (AEON)?

8 analysts have analysed AEON and the average price target is 5.3 USD. This implies a price increase of 400.38% is expected in the next year compared to the current price of 1.06.

What are the consensus estimates for AEON BIOPHARMA INC (AEON) next earnings?

The consensus EPS estimate for the next earnings of AEON BIOPHARMA INC (AEON) is -0.13 USD and the consensus revenue estimate is 0 USD.